MTA1: A Vital Modulator in Prostate Cancer

Ma, Jialu; Li, Chunxiao; Qian, Haili; Zhang, Yong

doi:10.2174/1389203723666220705152713

Cited by 2 publications

(1 citation statement)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…studied a novel AR/HDAC6 dual inhibitor, which showed a more potent anti-proliferative effect on PCa cells than an AR antagonist (MDV3100) ( 30 ). High expression levels of THOC1 ( 31 ), PNN ( 32 ), MTA1 ( 33 ), DDX17 ( 34 ), and CLK1 ( 35 ) have been shown to promote PCa progression. Niklaus et al.…”

Section: Discussionmentioning

confidence: 99%

Identification of bicalutamide resistance-related genes and prognosis prediction in patients with prostate cancer

Wang

Pan

et al. 2023

Front. Endocrinol.

View full text Add to dashboard Cite

BackgroundProstate cancer (PCa) is the second most common type of cancer and the fifth leading cause of cancer-related death in men. Androgen deprivation therapy (ADT) has become the first-line therapy for inhibiting PCa progression; however, nearly all patients receiving ADT eventually progress to castrate-resistant prostate cancer. Therefore, this study aimed to identify hub genes related to bicalutamide resistance in PCa and provide new insights into endocrine therapy resistance.MethodsThe data were obtained from public databases. Weighted correlation network analysis was used to identify the gene modules related to bicalutamide resistance, and the relationship between the samples and disease-free survival was analyzed. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses were performed, and hub genes were identified. The LASSO algorithm was used to develop a bicalutamide resistance prognostic model in patients with PCa, which was then verified. Finally, we analyzed the tumor mutational heterogeneity and immune microenvironment in both groups.ResultsTwo drug resistance gene modules were identified. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses revealed that both modules are involved in RNA splicing. The protein–protein interaction network identified 10 hub genes in the brown module LUC7L3, SNRNP70, PRPF3, LUC7L, CLASRP, CLK1, CLK2, U2AF1L4, NXF1, and THOC1) and 13 in the yellow module (PNN, PPWD1, SRRM2, DHX35, DMTF1, SALL4, MTA1, HDAC7, PHC1, ACIN1, HNRNPH1, DDX17, and HDAC6). The prognostic model composed of RNF207, REC8, DFNB59, HOXA2, EPOR, PILRB, LSMEM1, TCIRG1, ABTB1, ZNF276, ZNF540, and DPY19L2 could effectively predict patient prognosis. Genomic analysis revealed that the high- and low-risk groups had different mutation maps. Immune infiltration analysis showed a statistically significant difference in immune infiltration between the high- and low-risk groups, and that the high-risk group may benefit from immunotherapy.ConclusionIn this study, bicalutamide resistance genes and hub genes were identified in PCa, a risk model for predicting the prognosis of patients with PCa was constructed, and the tumor mutation heterogeneity and immune infiltration in high- and low-risk groups were analyzed. These findings offer new insights into ADT resistance targets and prognostic prediction in patients with PCa.

show abstract

Section: Discussionmentioning

confidence: 99%

Identification of bicalutamide resistance-related genes and prognosis prediction in patients with prostate cancer

Wang

Pan

et al. 2023

Front. Endocrinol.

View full text Add to dashboard Cite

show abstract

Metastasis‐associated 1 localizes to the sarcomeric Z‐disc and is implicated in skeletal muscle pathology

Xue,

Han,

Sun

et al. 2024

Cytoskeleton

View full text Add to dashboard Cite

Metastasis‐associated 1 (MTA1), a subunit of the nucleosome remodeling and histone deacetylation (NuRD) corepressor complex, was reported to be expressed in the cytoplasm of skeletal muscles. However, the exact subcellular localization and the functional implications of MTA1 in skeletal muscles have not been examined. This study aims to demonstrate the subcellular localization of MTA1 in skeletal muscles and reveal its possible roles in skeletal muscle pathogenesis. Striated muscles (skeletal and cardiac) from C57BL/6 mice of 4–5 weeks were collected to examine the expression of MTA1 by Western blotting and immunohistochemistry. Immunofluorescence and immunoelectron microscopy were performed for MTA1, α‐actinin (a Z‐disc marker protein), and SMN (survival of motor neuron) proteins. Gene Expression Omnibus (GEO) data sets were analyzed using the GEO2R online tool to explore the functional implications of MTA1 in skeletal muscles. MTA1 expression was detected by Western blotting and immunohistochemistry in skeletal and cardiac muscles. Subcellular localization of MTA1 was found in the Z‐disc of sarcomeres, where α‐actinin and SMN were expressed. Data mining of GEO profiles suggested that MTA1 dysregulation is associated with multiple skeletal muscle defects, such as Duchenne muscular dystrophy, Emery‐Dreifuss muscular dystrophy, nemaline myopathy, and dermatomyositis. The GEO analysis also showed that MTA1 expression gradually decreased with age in mouse skeletal muscle precursor cells. The subcellular localization of MTA1 in sarcomeres of skeletal muscles implies its biological roles in sarcomere structures and its possible contribution to skeletal muscle pathology.

show abstract

MTA1: A Vital Modulator in Prostate Cancer

Cited by 2 publications

References 72 publications

Identification of bicalutamide resistance-related genes and prognosis prediction in patients with prostate cancer

Identification of bicalutamide resistance-related genes and prognosis prediction in patients with prostate cancer

Metastasis‐associated 1 localizes to the sarcomeric Z‐disc and is implicated in skeletal muscle pathology

Contact Info

Product

Resources

About